Bulletin
Investor Alert

New York Markets Close in:

Ligand Pharmaceuticals Inc.

NAS: LGND

GO
/marketstate/country/us

Market open

 --Real time quotes

Sep 18, 2020, 1:07 p.m.

/zigman2/quotes/202030140/composite

$

91.70

Change

-2.45 -2.60%

Volume

Volume 121,375

Real time quotes

/zigman2/quotes/202030140/composite

Previous close

$ 94.15

$ 91.70

Change

-2.45 -2.60%

Day low

Day high

$91.47

$95.46

Open

52 week low

52 week high

$57.24

$127.80

Open

Company Description

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The ...

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Valuation

P/E Current

2.96

P/E Ratio (without extraordinary items)

3.27

Price to Sales Ratio

17.13

Price to Book Ratio

2.29

Enterprise Value to EBITDA

42.85

Enterprise Value to Sales

13.63

Total Debt to Enterprise Value

0.40

Efficiency

Revenue/Employee

1,045,930.00

Income Per Employee

5,472,191.00

Receivables Turnover

2.46

Total Asset Turnover

0.09

Liquidity

Current Ratio

66.09

Quick Ratio

65.66

Cash Ratio

62.97

Profitability

Gross Margin

55.45

Operating Margin

-4.76

Pretax Margin

662.31

Net Margin

523.19

Return on Assets

44.83

Return on Equity

94.76

Return on Total Capital

-0.44

Return on Invested Capital

48.65

Capital Structure

Total Debt to Total Equity

84.74

Total Debt to Total Capital

45.87

Total Debt to Total Assets

43.49

Long-Term Debt to Equity

84.58

Long-Term Debt to Total Capital

45.78

Officers and Executives

Name Age Officer Since Title
Mr. Matthew William Foehr 46 2011 Chief Operating Officer & Executive Vice President
Mr. John L. Higgins 49 2007 President, Chief Executive Officer & Director
Mr. Matthew Edward Korenberg 44 2015 Chief Financial Officer & Vice President-Finance
Dr. Eric Vajda - 2002 Vice President-Preclinical Research & Development
Mr. Brian Lundstrom 56 2012 Vice President

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
08/24/2020 Matthew William Foehr
President and COO
78   Disposition at $110.89 per share. 8,649
08/24/2020 Matthew William Foehr
President and COO
78   Derivative/Non-derivative trans. at $21.92 per share. 1,709
08/21/2020 Matthew William Foehr
President and COO
7,225   Disposition at $112.88 per share. 815,558
08/21/2020 Matthew William Foehr
President and COO
7,225   Derivative/Non-derivative trans. at $14.47 per share. 104,545
08/21/2020 Matthew William Foehr
President and COO
790   Derivative/Non-derivative trans. at $74.42 per share. 58,791
07/07/2020 John L. Higgins
Chief Executive Officer; Director
1,373   Derivative/Non-derivative trans. at $74.42 per share. 102,178
07/07/2020 John L. Higgins
Chief Executive Officer; Director
1,777   Derivative/Non-derivative trans. at $56.26 per share. 99,974
07/07/2020 John L. Higgins
Chief Executive Officer; Director
1,165   Derivative/Non-derivative trans. at $85.79 per share. 99,945
06/30/2020 Charles Stuart Berkman
SVP, Gen. Counsel & Secretary
238   21,189
06/30/2020 Matthew Edward Korenberg
EVP,Finance & Strategy and CFO
238   21,189
06/10/2020 Jason M. Aryeh
Director
831   Award at $0 per share. 0
06/10/2020 Todd C. Davis
Director
831   Award at $0 per share. 0
06/10/2020 John W. Kozarich
Director
831   Award at $0 per share. 0
06/10/2020 Sunil Patel
Director
831   Award at $0 per share. 0
06/10/2020 John L. LaMattina
Director
831   Award at $0 per share. 0
06/10/2020 Stephen L. Sabba
Director
831   Award at $0 per share. 0
06/10/2020 Nancy Ryan Gray
Director
831   Award at $0 per share. 0
06/10/2020 Sarah Boyce
Director
831   Award at $0 per share. 0
06/04/2020 Charles Stuart Berkman
SVP, Gen. Counsel & Secretary
11,146   Disposition at $118.59 per share. 1,321,804
03/13/2020 Matthew William Foehr
President and COO
2,000   Derivative/Non-derivative trans. at $21.92 per share. 43,840
02/27/2020 Matthew William Foehr
President and COO
1,706   Derivative/Non-derivative trans. at $21.92 per share. 37,395
02/27/2020 Matthew William Foehr
President and COO
7,225   Derivative/Non-derivative trans. at $14.47 per share. 104,545
02/27/2020 Matthew William Foehr
President and COO
7,225   Disposition at $110 per share. 794,750
02/15/2020 John L. Higgins
Chief Executive Officer; Director
2,117   Derivative/Non-derivative trans. at $97.23 per share. 205,835
02/15/2020 John L. Higgins
Chief Executive Officer; Director
1,310   Derivative/Non-derivative trans. at $97.23 per share. 127,371
02/15/2020 John L. Higgins
Chief Executive Officer; Director
1,689   Derivative/Non-derivative trans. at $97.23 per share. 164,221
02/15/2020 Matthew William Foehr
President and COO
1,170   Derivative/Non-derivative trans. at $97.23 per share. 113,759
02/15/2020 Matthew William Foehr
President and COO
447   Derivative/Non-derivative trans. at $97.23 per share. 43,461
02/15/2020 Matthew William Foehr
President and COO
869   Derivative/Non-derivative trans. at $97.23 per share. 84,492
02/15/2020 Charles Stuart Berkman
SVP, Gen. Counsel & Secretary
367   Derivative/Non-derivative trans. at $97.23 per share. 35,683
02/15/2020 Charles Stuart Berkman
SVP, Gen. Counsel & Secretary
207   Derivative/Non-derivative trans. at $97.23 per share. 20,126
02/15/2020 Charles Stuart Berkman
SVP, Gen. Counsel & Secretary
307   Derivative/Non-derivative trans. at $97.23 per share. 29,849
02/14/2020 Matthew William Foehr
President and COO
7,225   Disposition at $95.84 per share. 692,444
02/14/2020 Matthew William Foehr
President and COO
7,225   Derivative/Non-derivative trans. at $14.47 per share. 104,545
/news/latest/company/us/lgnd

MarketWatch News on LGND

  1. Landec and Evolent Health See Activist Action

    9:30 p.m. Aug. 28, 2020

    - Barron's Online

  2. Ligand Pharmaceuticals stock price target raised to $155 from $135 at Benchmark

    6:05 a.m. July 14, 2020

    - Tomi Kilgore

  3. Strategists Pick Winning Stocks for a Volatile Market

    12:43 p.m. June 12, 2020

    - Barron's Online

  4. Hedge Fund Alleges SEC Bias in Short-Selling Case

    7:30 a.m. Feb. 19, 2020

    - Barron's Online

  5. Ligand Pharmaceuticals started at buy with $135 stock price target at Benchmark

    9:25 a.m. Feb. 6, 2020

    - Tomi Kilgore

  6. Here’s how Wall Street’s favorite stock picks turned out in 2019

    10:48 a.m. Dec. 21, 2019

    - Philip van Doorn

  7. Top stock picks for 2020: Making money with midsize firms

    11:41 p.m. Dec. 12, 2019

    - Philip van Doorn

  8. Ligand Pharmaceuticals sets new $500 mln stock repurchase program

    6:32 a.m. Sept. 12, 2019

    - Tomi Kilgore

  9. Like Amazon, these stocks have 100% buy ratings from analysts

    7:24 a.m. April 25, 2019

    - Philip van Doorn

  10. Ligand Pharma shares slide 17% after short seller Citron says pipeline is a 'pipe dream'

    2:00 p.m. Jan. 16, 2019

    - Ciara Linnane

  11. These are the top stock picks for 2019 among Wall Street analysts

    8:21 a.m. Jan. 4, 2019

    - Philip van Doorn

  12. Tesla CEO Elon Musk Is Wrong About Short Sellers

    11:32 a.m. Oct. 16, 2018

    - Barron's Online

  13. Loading more headlines...
/news/nonmarketwatch/company/us/lgnd

Other News on LGND

  1. Ligand Pharmaceuticals Enters Oversold Territory

    7:16 a.m. Today

    - Zacks.com

  2. LGND or ALKS: Which Is the Better Value Stock Right Now?

    11:40 a.m. Sept. 9, 2020

    - Zacks.com

  3. How To Predict Sales Growth

    3:23 p.m. Sept. 8, 2020

    - Seeking Alpha

  4. LGND vs. ILMN: Which Stock Is the Better Value Option?

    11:40 a.m. Aug. 24, 2020

    - Zacks.com

  5. Merger Arbitrage Mondays - Qiagen Shareholders Want More

    8:04 a.m. Aug. 17, 2020

    - Seeking Alpha

  6. Ligand Pharmaceuticals - Still, Many Moving Parts

    7:04 a.m. Aug. 13, 2020

    - Seeking Alpha

  7. Ligand to buy Pfenex for up to $516M deal value

    6:03 p.m. Aug. 10, 2020

    - Seeking Alpha

  8. 10-Q: LIGAND PHARMACEUTICALS INC

    5:29 p.m. Aug. 7, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  9. CStone antibody successful in late-stage lung cancer study

    9:24 a.m. Aug. 7, 2020

    - Seeking Alpha

  10. Ligand (LGND) Beats on Q2 Earnings & Sales, Raises View

    11:01 a.m. Aug. 4, 2020

    - Zacks.com

  11. Loading more headlines...

At a Glance

Ligand Pharmaceuticals, Inc.

3911 Sorrento Valley Boulevard

Suite 110

San Diego, California 92121

Phone

1 8585507500

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

Revenue

$120.28M

Net Income

$629.30M

Employees

115.00

/news/pressrelease/company/us/lgnd

Press Releases on LGND

  1. SHAREHOLDER ALERT: WeissLaw LLP Investigates Pfenex, Inc.

    9:05 p.m. Aug. 11, 2020

    - PR Newswire - PRF

  2. Ligand Buying Pfenex

    10:00 a.m. Aug. 11, 2020

    - Baystreet.ca

  3. Ligand to Acquire Pfenex Inc.

    5:36 p.m. Aug. 10, 2020

    - BusinessWire - BZX

  4. Ligand Reports Second Quarter 2020 Financial Results

    7:30 a.m. Aug. 3, 2020

    - BusinessWire - BZX

  5. Ligand’s Second Quarter Financial Results to be Reported August 3rd

    4:28 p.m. July 16, 2020

    - BusinessWire - BZX

  6. Loading more headlines...
Trending Tickers
  • /quotes/zigman/17636479/composite VUZI+15.60%
  • /quotes/zigman/237947/composite JCP-5.83%
  • /quotes/zigman/59392505/composite NUGT-2.93%
  • /quotes/zigman/59386294/composite JNUG-5.94%
  • /quotes/zigman/65801738/composite TLT+1.11%
X
Powered by StockTwits
Link to MarketWatch's Slice.